Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Stock Holdings Increased by Vontobel Holding Ltd.

Vontobel Holding Ltd. grew its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 32.5% during the third quarter, HoldingsChannel reports. The institutional investor owned 18,940 shares of the biotechnology company’s stock after buying an additional 4,647 shares during the quarter. Vontobel Holding Ltd.’s holdings in Iovance Biotherapeutics were worth $178,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in IOVA. ORG Partners LLC acquired a new stake in shares of Iovance Biotherapeutics during the 2nd quarter valued at approximately $32,000. Quest Partners LLC raised its holdings in shares of Iovance Biotherapeutics by 1,237.7% during the second quarter. Quest Partners LLC now owns 5,003 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 4,629 shares during the period. Fidelis Capital Partners LLC bought a new position in shares of Iovance Biotherapeutics in the 1st quarter worth about $87,000. EverSource Wealth Advisors LLC acquired a new position in shares of Iovance Biotherapeutics in the 2nd quarter valued at about $58,000. Finally, Daiwa Securities Group Inc. grew its position in shares of Iovance Biotherapeutics by 754.0% during the 2nd quarter. Daiwa Securities Group Inc. now owns 8,813 shares of the biotechnology company’s stock valued at $71,000 after buying an additional 7,781 shares during the last quarter. Institutional investors and hedge funds own 77.03% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Piper Sandler lowered Iovance Biotherapeutics from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $19.00 to $10.00 in a report on Monday, July 29th. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 target price on shares of Iovance Biotherapeutics in a research report on Monday, August 12th. Finally, StockNews.com raised shares of Iovance Biotherapeutics to a “sell” rating in a report on Monday, August 12th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.00.

Iovance Biotherapeutics Stock Down 1.4 %

Shares of IOVA opened at $9.82 on Thursday. Iovance Biotherapeutics, Inc. has a 52-week low of $3.47 and a 52-week high of $18.33. The firm has a market capitalization of $2.75 billion, a PE ratio of -5.46 and a beta of 0.62. The firm has a 50-day moving average price of $10.25 and a 200 day moving average price of $9.90.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.01. Iovance Biotherapeutics had a negative net margin of 1,343.27% and a negative return on equity of 65.04%. The business had revenue of $31.11 million during the quarter, compared to analysts’ expectations of $24.59 million. During the same period last year, the firm posted ($0.47) earnings per share. The business’s revenue was up 12969.7% on a year-over-year basis. On average, equities analysts expect that Iovance Biotherapeutics, Inc. will post -1.26 EPS for the current year.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.